Antineoplastics
1
Reactions 397 - 18 Apr 1992 Antineoplastics Adverse effects: clinical study Fatigue syndrome lasting 4-8 weeks, chemical and ischaemic hepatitis, severe thrombocytopenia and icterus occurred following whole liver chemoembolisation in 7 evaluable patients. The patients had unresectable colorectal cancer, metastatic to the liver, and good performance status They received ’Angiostat’, a vaso-occlusive collagen, mitomycin, doxorubicin +/- cisplatin. The authors suggested limiting the use of chemoembolisation in metastatic colorectal cancer to patients whose disease continues to progress after systemic or hepatic arterial antineoplastic therapy. They also suggested performing staged unilobar chemoembolisations at 4- to 6-week intervals rather than whole liver chemoembolisation in order to reduce toxicity Borner M, et al. Considerable side effects of chemoembolization for colorectal carcinoma metastatic to the liver cancer. Annals of Oncology 3: 113-115, Feb 1992 - Switzerland 800127310 1 Reactions 18 Apr 1992 No. 397 0114-9954/10/0397-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of Antineoplastics
Reactions 397 - 18 Apr 1992
Antineoplastics
Adverse effects: clinical studyFatigue syndrome lasting 4-8 weeks, chemical and
ischaemic hepatitis, severe thrombocytopenia and icterusoccurred following whole liver chemoembolisation in 7evaluable patients. The patients had unresectable colorectalcancer, metastatic to the liver, and good performance statusThey received ’Angiostat’, a vaso-occlusive collagen,mitomycin, doxorubicin +/- cisplatin.
The authors suggested limiting the use ofchemoembolisation in metastatic colorectal cancer to patientswhose disease continues to progress after systemic or hepaticarterial antineoplastic therapy. They also suggestedperforming staged unilobar chemoembolisations at 4- to6-week intervals rather than whole liver chemoembolisation inorder to reduce toxicityBorner M, et al. Considerable side effects of chemoembolization for colorectalcarcinoma metastatic to the liver cancer. Annals of Oncology 3: 113-115, Feb 1992- Switzerland 800127310
1
Reactions 18 Apr 1992 No. 3970114-9954/10/0397-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
